| Latest Genitope News Headlines |
| Date | Time | Source | |
| 05/21/2007 | 11:00AM | PRNUS | Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Ri
FREMONT, Calif., May 21 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced the initiation of a Phase 2 clinical trial evaluating the use of MyVax(R) personalized immunotherapy following primary treatment with rituximab and chemotherapy (R-Chemo) for follicular non-Hodgkin's lymphoma (fNHL... More...>> |
| 07/27/2006 | 11:51PM | PRNUS | Data Safety Monitoring Board Recommends Continuation of MyVax(R) Personalized Immunotherapy Phase 3 Trial After Second Interim
Conference Call to be Held Friday, July 28 at 9:00 AM EDT
REDWOOD CITY, Calif., July 27 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that its independent Data Safety Monitoring Board (DSMB) reviewed the second planned interim analysis of data for efficacy in its pivotal Phase 3 clinical... More...>> |
| 06/13/2006 | 8:00AM | PRNUS | FDA Grants Fast Track Status to MyVax(R) Personalized Immunotherapy for Follicular Non-Hodgkin's Lymphoma
REDWOOD CITY, Calif., June 13 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that MyVax(R) personalized immunotherapy received Fast Track designation from the U.S. Food & Drug Administration (FDA) for the treatment of follicular non-Hodgkin's Lymphoma (fNHL).
The FDA grants Fast Track... More...>> |
| 05/16/2006 | 8:00AM | PRNUS | Genitope Corporation Appoints Dr. Mary Rybak Vice President of Medical Affairs
REDWOOD CITY, Calif., May 16 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced the appointment of Mary Rybak, M.D., as the company's vice president of medical affairs. Dr. Rybak will be responsible for working with Genitope's executive team to establish and execute the company's long-term... More...>> |
| 05/09/2006 | 8:30AM | PRNUS | M. D. Anderson Cancer Center Initiates Clinical Trial to Evaluate a Custom-Made Therapeutic Vaccine for the Treatment of Chroni
REDWOOD CITY, Calif., May 9 /PRNewswire-FirstCall/ -- The University of Texas M. D. Anderson Cancer Center has initiated a clinical trial to evaluate the use of an idiotype active immunotherapy, also referred to as idiotype vaccine therapy, in patients with Chronic Lymphocytic Leukemia (CLL), a type of cancer affecting... More...>> |
| 05/02/2006 | 1:31PM | PRNUS | /C O R R E C T I O N -- Genitope Corporation/
In the news release, Genitope Corporation (NASDAQ:GTOP) to Present Phase 2 Clinical Trial Data at American Society of Clinical Oncology Annual Meeting, issued earlier today by Genitope Corporation over PR Newswire, we are advised by the company that the date at the end of the first paragraph, should read "Monday, June... More...>> |
| 05/02/2006 | 8:30AM | PRNUS | Genitope Corporation to Present Phase 2 Clinical Trial Data at American Society of Clinical Oncology Annual Meeting
REDWOOD CITY, Calif., May 2 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that data from its ongoing Phase 2 clinical trial evaluating MyVax(R) personalized immunotherapy following rituximab as a treatment for follicular Non-Hodgkin's Lymphoma (fNHL) has been accepted for presentation... More...>> |
| 03/31/2006 | 6:32PM | PRNUS | Genitope Corporation Announces Financial Results for Fourth Quarter and Year Ended December 31, 2005
REDWOOD CITY, Calif., March 31 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today reported financial results for the fourth quarter and year ended December 31, 2005.
2005 Corporate Progress and Outlook
"2005 was a very important year for Genitope Corporation," said Dan W. Denney Jr., Ph.D., Genitope... More...>> |
| 03/16/2006 | 8:00AM | PRNUS | Genitope Corporation Announces Timing of Release of Financial Results for Fourth Quarter and Year Ended December 31, 2005
REDWOOD CITY, Calif., March 16 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced the timing of its release of financial results for the fourth quarter and year ended December 31, 2005.
Genitope Corporation expects to release its financial results for the fourth quarter and year ended December... More...>> |
| 02/27/2006 | 8:30AM | PRNUS | Genitope Corporation Initiates Clinical Trial to Evaluate MyVax(R) Personalized Immunotherapy in the Treatment of Chronic Lymph
REDWOOD CITY, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced the initiation of a clinical trial to evaluate the use of MyVax(R) personalized immunotherapy to treat Chronic Lymphocytic Leukemia (CLL), a type of cancer affecting the blood and bone marrow. MyVax(R) personalized... More...>> |
| 02/17/2006 | 10:18AM | PRNUS | Genitope Corporation Announces Exercise of Over-Allotment Option
REDWOOD CITY, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that the underwriters of its follow-on public offering of 6,400,000 shares have exercised in full their over-allotment option, purchasing 960,000 additional shares of common stock. Including the over-allotment... More...>> |
| 02/07/2006 | 6:21AM | PRNUS | Genitope Corporation Announces Pricing of Common Stock Offering
REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced the pricing of its public offering of 6,400,000 shares of its common stock at a price of $8.50 per share. Genitope Corporation has granted the underwriters an option to purchase up to an additional 960,000 shares... More...>> |
| 01/23/2006 | 7:00AM | PRNUS | Genitope Corporation Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced plans to offer 4,500,000 shares of its common stock in an underwritten public offering. The offering will be made pursuant to the Genitope Corporation's effective shelf registration statement previously filed with... More...>> |
| 12/12/2005 | 8:30AM | PRNUS | Phase II Clinical Results Indicate That MyVax(R) Personalized Immunotherapy Significantly Increases Median Time to Progression o
Long-Term Phase II Follow-Up Data Presented at American Society of Hematology Annual Meeting
ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Long-term follow-up results from a phase II clinical trial of Genitope Corporation's (NASDAQ:GTOP) MyVax(R) Personalized Immunotherapy as a treatment for follicular Non- Hodgkin's Lymphoma... More...>> |
| 12/08/2005 | 1:54PM | PRNUS | Genitope Corporation Files Patents For Personalized, Therapeutic Monoclonal Antibodies To Treat Non-Hodgkin's Lymphoma
Antibodies Directed Against Specific Regions of the B-cell Receptor May Allow Targeting of Non-Hodgkin's Lymphoma Patient Subsets
More...>> |
| 12/08/2005 | 1:54PM | PRNUS | Genitope Corporation Files Patents For Personalized, Therapeutic Monoclonal Antibodies To Treat Non-Hodgkin's Lymphoma
Antibodies Directed Against Specific Regions of the B-cell Receptor May Allow Targeting of Non-Hodgkin's Lymphoma Patient Subsets
REDWOOD CITY, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced the filing of two patents for the composition and use of a panel of monoclonal antibodies... More...>> |
| 11/08/2005 | 8:00AM | PRNUS | Genitope Corporation Announces Financial Results for Third Quarter and Nine Months Ended September 30, 2005
REDWOOD CITY, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) announced today financial results for the third quarter and nine months ended September 30, 2005.
Financial Results
For the third quarter of 2005, Genitope Corporation reported total operating expenses of $9.3 million and a net... More...>> |
| 11/02/2005 | 8:00AM | PRNUS | Genitope Corporation to Present at Rodman and Renshaw Techvest 7th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that the company will be presenting at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference in New York City on November 8th, 2005.
The presentation will be given by Dan W. Denney, Jr., Ph.D., chairman... More...>> |
| 09/19/2005 | 8:00AM | PRNUS | Genitope Corporation to Present at UBS Global Life Sciences Conference
REDWOOD CITY, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that the company will be presenting at the UBS Global Life Sciences Conference in New York City on September 26th, 2005.
The presentation will be given by Dan W. Denney, Jr., Ph.D., chairman of the board and... More...>> |
| 09/06/2005 | 8:01AM | PRNUS | Genitope Corporation to Present at Bear Stearns Healthcare Conference
REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Genitope Corporation (NASDAQ:GTOP) today announced that the company will be presenting at the Bear Stearns Healthcare Conference in New York City.
The presentation will be given by Dan W. Denney, Jr., Ph.D., chairman of the board and chief executive officer, and... More...>> |